Clinical and Radiological Features of Myelin Oligodendrocyte Glycoprotein-Associated Myelitis in Adults

키워드

참고문헌 (77)

1. Lennon VA, "A serum autoantibody marker of neuromyelitis optica : distinction from multiple sclerosis", Lancet, 364, pp.2106~2112 (2004)
2. Lennon VA, "IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4water channel", J Exp Med, 202, pp.473~477 (2005)
3. Wingerchuk DM, "International consensus diagnostic criteria for neuromyelitis optica spectrum disorders", Neurology, 85, pp.177~189 (2015)
4. Kitley J, "Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype", Neurology, 79, pp.1273~1277 (2012)
5. Sato DK, "Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders", Neurology, 82, pp.474~481 (2014)
6. Cobo-Calvo A, "Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults : the MOGADOR study", Neurology, 90, pp.e1858~e1869 (2018)
7. Ramanathan S, "Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination", J Neurol Neurosurg Psychiatry, 89, pp.127~137 (2018)
8. Marignier R, "Myelin-oligodendrocyte glycoprotein antibodyassociated disease", Lancet Neurol, 20, pp.762~772 (2021)
9. Takai Y, "Myelin oligodendrocyte glycoprotein antibody-associated disease : an immunopathological study", Brain, 143, pp.1431~1446 (2020)
10. Reindl M, "Myelin oligodendrocyte glycoprotein antibodies in neurological disease", Nat Rev Neurol, 15, pp.89~102 (2019)
11. Pham-Dinh D, "Myelin", oligodendrocyte glycoprotein is a member of a subset of the immunoglobulin superfamily encoded within the major histocompatibility complex, 1993, pp.90, 7990~7994
12. Jarius S, "MOG encephalomyelitis : international recommendations on diagnosis and antibody testing", J Neuroinflammation, 15, pp.134~ (2018)
13. Jarius S, "Neuromyelitis optica", Nat Rev Dis Primers, 6, pp.85~ (2020)
14. Jarius S, "MOG-IgG in NMO and related disorders : a multicenter study of 50 patients. Part 2 : epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome", J Neuroinflammation, 13, pp.280~ (2016)
15. Kunchok A, "Coexistence of myelin oligodendrocyte glycoprotein and aquaporin-4antibodies in adult and pediatric patients", JAMA Neurol, 77, pp.257~259 (2020)
16. Sepúlveda M, "Epidemiology of NMOSD in Catalonia : influence of the new 2015 criteria in incidence and prevalence estimates", Mult Scler, 24, pp.1843~1851 (2018)
17. de Mol CL, "Incidence and outcome of acquired demyelinating syndromes in Dutch children : update of a nationwide and prospective study", J Neurol, 265, pp.1310~1319 (2018)
18. Hennes EM, "Prognostic relevance of MOG antibodies in children with an acquired demyelinating syndrome", Neurology, 89, pp.900~908 (2017)
19. Hyun JW, "Comparison of MOG and AQP4 antibody seroprevalence in Korean adults with inflammatory demyelinating CNS diseases", Mult Scler, 27, pp.964~967 (2021)
20. Hyun JW, "Longitudinal analysis of myelin oligodendrocyte glycoprotein antibodies in CNS inflammatory diseases", J Neurol Neurosurg Psychiatry, 88, pp.811~817 (2017)
21. Kim SM, "Antibodies to MOG in adults with inflammatory demyelinating disease of the CNS", Neurol Neuroimmunol Neuroinflamm, 2, pp.e163~ (2015)
22. López-Chiriboga AS, "Association of MOG-IgG serostatus with relapse after acute disseminated encephalomyelitis and proposed diagnostic criteria for MOG-IgG–associated disorders", JAMA Neurol, 75, pp.1355~1363 (2018)
23. Rossor T, "Early predictors of epilepsy and subsequent relapse in children with acute disseminated encephalomyelitis", Mult Scler, 26, pp.333~342 (2020)
24. Soelberg K, "A population-based prospective study of optic neuritis", Mult Scler, 23, pp.1893~1901 (2017)
25. Chen JJ, "Prevalence of myelin oligodendrocyte glycoprotein and aquaporin-4–IgG in patients in the Optic Neuritis Treatment Trial", JAMA Ophthalmol, 136, pp.419~422 (2018)
26. Sechi E, "Positive predictive value of myelin oligodendrocyte glycoprotein autoantibody testing", JAMA Neurol, 78, pp.741~746 (2021)
27. Jurynczyk M, "Clinical presentation and prognosis in MOG-antibody disease : a UK study", Brain, 140, pp.3128~3138 (2017)
28. de Mol CL, "The clinical spectrum and incidence of anti-MOG-associated acquired demyelinating syndromes in children and adults", Mult Scler, 26, pp.806~814 (2020)
29. Hamid SHM, "What proportion of AQP4-IgG-negative NMO spectrum disorder patients are MOG-IgG positive? A cross sectional study of 132 patients", J Neurol, 264, pp.2088~2094 (2017)
30. Hyun JW, "Idiopathic aquaporin-4 antibody negative longitudinally extensive transverse myelitis", Mult Scler, 21, pp.710~717 (2015)
31. Cobo-Calvo Á, "Antibodies to myelin oligodendrocyte glycoprotein in aquaporin 4 antibody seronegative longitudinally extensive transverse myelitis : clinical and prognostic implications", Mult Scler, 22, pp.312~319 (2016)
32. Cobo-Calvo Á, "Frequency of myelin oligodendrocyte glycoprotein antibody in multiple sclerosis : a multicenter cross-sectional study", Neurol Neuroimmunol Neuroinflamm, 7, pp.e649~ (2019)
33. Cobo-Calvo A, "Clinical features and risk of relapse in children and adults with myelin oligodendrocyte glycoprotein antibody-associated disease", Ann Neurol, 89, pp.30~41 (2021)
34. Alshamrani F, "Case series : myelin oligodendrocyte glycoprotein-immunoglobulin G-related disease spectrum", Front Neurol, 11, pp.89~ (2020)
35. Cobo-Calvo A, "Evaluation of treatment response in adults with relapsing MOG-Ab-associated disease", J Neuroinflammation, 16, pp.134~ (2019)
36. Liu J, "Anti-MOG antibody-associated disorders : differences in clinical profiles and prognosis in Japan and Germany", J Neurol Neurosurg Psychiatry (2020)[DOI]
37. Sepúlveda M, "Clinical spectrum associated with MOG autoimmunity in adults : significance of sharing rodent MOG epitopes", J Neurol, 263, pp.1349~1360 (2016)
38. Netravathi M, "Myelin oligodendrocyte glycoprotein-antibody-associated disorder : a new inflammatory CNS demyelinating disorder", J Neurol, 268, pp.1419~1433 (2021)
39. Cobo-Calvo Á, "MOG antibody-related disorders : common features and uncommon presentations", J Neurol, 264, pp.1945~1955 (2017)
40. Ciron J, "Frequency and characteristics of short versus longitudinally extensive myelitis in adults with MOG antibodies : a retrospective multicentric study", Mult Scler, 26, pp.936~944 (2020)
41. Mariano R, "Comparison of clinical outcomes of transverse myelitis among adults with myelin oligodendrocyte glycoprotein antibody vs aquaporin-4 antibody disease", JAMA Netw Open, 2, pp.e1912732~ (2019)
42. Dubey D, "Clinical, radiologic, and prognostic features of myelitis associated with myelin oligodendrocyte glycoprotein autoantibody", JAMA Neurol, 76, pp.301~309 (2019)
43. ZhangBao J, "Myelitis in inflammatory disorders associated with myelin oligodendrocyte glycoprotein antibody and aquaporin-4 antibody : a comparative study in Chinese Han patients", Eur J Neurol, 28, pp.1308~1315 (2021)
44. Asseyer S, "Pain, depression, and quality of life in adults with MOG-antibody-associated disease", Eur J Neurol, 28, pp.1645~1658 (2021)
45. Zhao S, "Neuropathic pain in neuromyelitis optica affects activities of daily living and quality of life", Mult Scler, 20, pp.1658~1661 (2014)
46. Kim SM, "Painful tonic spasm in neuromyelitis optica : incidence, diagnostic utility, and clinical characteristics", Arch Neurol, 69, pp.1026~1031 (2012)
47. Li QY, "Painful tonic spasm in Chinese patients with neuromyelitis optica spectrum disorder : prevalence, subtype, and features", Mult Scler Relat Disord, 45, pp.102408~ (2020)
48. Liu J, "Painful tonic spasm in neuromyelitis optica spectrum disorders : prevalence, clinical implications and treatment options", Mult Scler Relat Disord, 17, pp.99~102 (2017)
49. Waters P, "Serial anti-myelin oligodendrocyte glycoprotein antibody analyses and outcomes in children with demyelinating syndromes", JAMA Neurol, 77, pp.82~93 (2020)
50. Duignan S, "Myelin oligodendrocyte glycoprotein and aquaporin-4 antibodies are highly specific in children with acquired demyelinating syndromes", Dev Med Child Neurol, 60, pp.958~962 (2018)
51. Lechner C, "Antibodies to MOG and AQP4 in children with neuromyelitis optica and limited forms of the disease", J Neurol Neurosurg Psychiatry, 87, pp.897~905 (2016)
52. Kitley J, "Prognostic factors and disease course in aquaporin-4 antibodypositive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan", Brain, 135(Pt 6), pp.1834~1849 (2012)
53. Höftberger R, "Antibodies to MOG and AQP4 in adults with neuromyelitis optica and suspected limited forms of the disease", Mult Scler, 21, pp.866~874 (2015)
54. Zhou Y, "Myelin oligodendrocyte glycoprotein antibody-associated demyelination : comparison between onset phenotypes", Eur J Neurol, 26, pp.175~183 (2019)
55. Beekman J, "Neuromyelitis optica spectrum disorder : patient experience and quality of life", Neurol Neuroimmunol Neuroinflamm, 6, pp.e580~ (2019)
56. Mariano R, "Quantitative spinal cord MRI in MOG-antibody disease, neuromyelitis optica and multiple sclerosis", Brain, 144, pp.198~212 (2021)
57. Kitley J, "Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies : a comparative study", JAMA Neurol, 71, pp.276~283 (2014)
58. Etemadifar M, "Conus medullaris involvement in demyelinating disorders of the CNS : a comparative study", Mult Scler Relat Disord, 54, pp.103127~ (2021)
59. Vazquez Do Campo R, "MOG antibodies in combined central and peripheral demyelination syndromes", Neurol Neuroimmunol Neuroinflamm, 5, pp.e503~ (2018)
60. Tantsis EM, "Magnetic resonance imaging in enterovirus-71, myelin oligodendrocyte glycoprotein antibody, aquaporin-4 antibody, and multiple sclerosis-associated myelitis in children", Dev Med Child Neurol, 61, pp.1108~1116 (2019)
61. Sundaram S, "Relapsing lumbosacral myeloradiculitis : an unusual presentation of MOG antibody disease", Mult Scler, 26, pp.509~511 (2020)
62. Salama S, "Radiological characteristics of myelin oligodendrocyte glycoprotein antibody disease", Mult Scler Relat Disord, 29, pp.15~22 (2019)
63. Sechi E, "Comparison of MRI lesion evolution in different central nervous system demyelinating disorders", Neurology, 97, pp.e1097~e1109 (2021)
64. Hyun JW, "Bright spotty lesions on the spinal cord : an additional MRI indicator of neuromyelitis optica spectrum disorder?", J Neurol Neurosurg Psychiatry, 86, pp.1280~1282 (2015)
65. Yonezu T, ""Bright spotty lesions"on spinal magnetic resonance imaging differentiate neuromyelitis optica from multiple sclerosis", Mult Scler, 20, pp.331~337 (2014)
66. Rabasté S, "Diagnostic value of bright spotty lesions on MRI after a first episode of acute myelopathy", J Neuroradiol, 48, pp.28~36 (2021)
67. Hyun JW, "Brighter spotty lesions on spinal MRI help differentiate AQP4 antibody-positive NMOSD from MOGAD", Mult Scler (2021)[DOI]
68. Chien C, "Spinal cord lesions and atrophy in NMOSD with AQP4-IgG and MOG-IgG associated autoimmunity", Mult Scler, 25, pp.1926~1936 (2019)
69. Macaron G, "MOG-related disorders : a new cause of imaging-negative myelitis?", Mult Scler, 26, pp.511~515 (2020)
70. Sechi E, "Frequency and characteristics of MRI-negative myelitis associated with MOG autoantibodies", Mult Scler, 27, pp.303~308 (2021)
71. Sechi E, "Variability of cerebrospinal fluid findings by attack phenotype in myelin oligodendrocyte glycoprotein-IgG-associated disorder", Mult Scler Relat Disord, 47, pp.102638~ (2021)
72. Loos J, "MOG encephalomyelitis : distinct clinical, MRI and CSF features in patients with longitudinal extensive transverse myelitis as first clinical presentation", J Neurol, 267, pp.1632~1642 (2020)
73. Dobson R, "Cerebrospinal fluid oligoclonal bands in multiple sclerosis and clinically isolated syndromes : a meta-analysis of prevalence, prognosis and effect of latitude", J Neurol Neurosurg Psychiatry, 84, pp.909~914 (2013)
74. Kim KH, "Reappraisal of CSFspecific oligoclonal bands in Asia", Mult Scler, 28, pp.665~668 (2022)
75. Zalewski NL, "Characteristics of spontaneous spinal cord infarction and proposed diagnostic criteria", JAMA Neurol, 76, pp.56~63 (2019)
76. Jarius S, "MOG-IgG in primary and secondary chronic progressive multiple sclerosis : a multicenter study of 200 patients and review of the literature", J Neuroinflammation, 15, pp.88~ (2018)
77. Marcucci SB, "Progressive myelopathy in myelin oligodendrocyte glycoprotein antibody-associated disease : a new mimicker of progressive multiple sclerosis?", Mult Scler Relat Disord, 52, pp.102964~ (2021)

관련 논문AI추천